학술논문
Target product profile: Trypanosoma brucei gambiense test to verify elimination.
Document Type
Academic Journal
Author
Priotto G; Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland.; Franco JR; Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland.; Lejon V; Institut de Recherche pour le Développement, CIRAD, University of Montpellier, France.; Büscher P; Institute of Tropical Medicine, Antwerp, Belgium.; Matovu E; College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda.; Ndung'u J; Foundation for Innovative New Diagnostics-Kenya, Nairobi, Kenya.; Biéler S; Neglected Tropical Diseases Programme, Foundation for Innovative New Diagnostics, Geneva, Switzerland.; Mumba D; Department of Parasitology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.; Van Reet N; Institute of Tropical Medicine, Antwerp, Belgium.; Verlé P; Institute of Tropical Medicine, Antwerp, Belgium.; Jamonneau V; Institut de Recherche pour le Développement, CIRAD, University of Montpellier, France.; Simarro PP; Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland.; Ebeja AK; Communicable Disease Unit, World Health Organization Regional Office for Africa, Brazzaville, Congo.; Sankara D; Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland.; Dagne DA; Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland.
Source
Publisher: World Health Organization Country of Publication: Switzerland NLM ID: 7507052 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1564-0604 (Electronic) Linking ISSN: 00429686 NLM ISO Abbreviation: Bull World Health Organ Subsets: MEDLINE
Subject
Language
English
Abstract
Human African trypanosomiasis is a life-threatening parasitic infection transmitted by the tsetse fly in sub-Saharan Africa. The most common form is caused by Trypanosoma brucei gambiense , with humans as the main reservoir. Diagnosis in the field requires microscopic examination performed by specifically trained personnel. After over two decades of sustained efforts, the incidence of the disease is strongly declining, and some historically endemic countries are no longer detecting cases. The World Health Organization (WHO) has targeted the elimination of transmission of gambiense human African trypanosomiasis by 2030, defined as zero autochthonous cases for at least five consecutive years. Endemic countries reaching this goal must maintain dedicated surveillance to detect re-emergence or re-introduction. With this new agenda, new tools are needed for verification of the absence of transmission. WHO has therefore developed a target product profile calling for development of a method for population-level cross-cutting surveillance of T. b. gambiense transmission. The method needs to be performed in national or sub-national reference laboratories, and to test in parallel numerous samples shipped from remote rural areas. Among other characteristics the product profile specifies: (i) a simple specimen collection procedure; (ii) no cold-chain requirement to transfer specimens to reference laboratories; (iii) high sensitivity and specificity; (iv) high-throughput, substantially automatized; (v) low cost per specimen, when analysed in large batches; and (vi) applicable also in animals.
((c) 2023 The authors; licensee World Health Organization.)
((c) 2023 The authors; licensee World Health Organization.)